Effects of 2 years' treatment of osteoporosis with 1 α-hydroxy vitamin D3 on bone mineral density and incidence of fracture: A placebo-controlled, double-blind prospective study

91Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

A two-year double-bund study monitored and evaluated the effects of 1α-hydroxy vitamin D3 (1α(OH)D3) on the lumbar (L2-4BMD) and total body bone mineral densities (TBBMD) and occurrence of fracture in 113 female osteoporotic patients receiving 0.75 μg/day of 1α(OH)D3 (n=57) or a placebo (n=56) with calcium supplementation in both groups. L2-4BMD increased 1.81% and 2.32% after one and 2 years in the 1α(OH)D3 group, but decreased 1.89% (P<0.05) and 0.28% in the placebo group. A significant difference (P<0.01) existed between the two groups after one year. TBBMD decreased significantly in the placebo group by 3.34% (P<0.01) and 3.52% after one and 2 years. Six new fractures occurred in the control group, but only two in the 1α(OH)D3 group (Odd's ratio=0.343, 95% confidence range; 0.0648-1.815). There were no serious adverse effects of the 1α(OH)D3 treatment. It was concluded that two-year treatment with 1α(OH)D3 increased the lumbar BMD and inhibited the decrease in TBBMD. Altough it was not significant, new fracture occurrence in the 1α(OH)D3 group was around 1/3 of that in the control group.

Cite

CITATION STYLE

APA

Shiraki, M., Kushida, K., Yamazaki, K., Nagai, T., Inoue, T., & Orimo, H. (1996). Effects of 2 years’ treatment of osteoporosis with 1 α-hydroxy vitamin D3 on bone mineral density and incidence of fracture: A placebo-controlled, double-blind prospective study. Endocrine Journal, 43(2), 211–220. https://doi.org/10.1507/endocrj.43.211

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free